In ablation strategy for persistent Atrial Fibrillation (PsAF), ablation limited to Pulmonary Vein (PV) isolation is the most straightforward approach but the result give only 50% of arrhythmia free follow-up. Substrate modification strategies have failed to demonstrate their superiority with variable reported success rate. The Marshall network is a highly arrhythmogenic structure that has not been incorporated in current ablation strategies. The investigators sought to investigate a new ablation strategy that target systematically the vein of Marshall by ethanol infusion. This step is integrated in a new ablation strategy consisting in a global anatomical substrate based ablation including PV isolation and left atrial linear ablation (Marshall-Plan). The main objective of this study is to compare the 12 month freedom from any arrhythmia (Atrial Fibrillation (AF)/Atrial Tachycardia (AT)) between the Marshall-Plan approach and the PV isolation approach.
Ablation strategy for persistent AF besides pulmonary vein isolation remains controversial. Indeed, two approaches have prevailed over the past two decades "cox-maze" strategy and mapping of the left atrium but both methods have failed to decrease AF recurrences (as shown by the clinical trial STAR AF 2). Two studies have demonstrated that the ligament of Marshall (LOM) could be the source of focal activities, the substrate of reentries and a strong parasympathetic modulator. For these reasons, LOM may represent a major target in AF treatment besides PV isolation. Nevertheless, conventional ablation techniques do not ensure the complete destruction of Marshall's musculature and parasympathetic ganglia that surround it, largely isolated by a sheath of adipose tissue. To overcome this technical limitation, LOM elimination can be achieved by alcohol injection into the vein of Marshall.The investigator innovative approach called Marshall Plan will then consists in 3 steps: 1) the destruction of Marshall bundles by ethanol infusion followed by the ablation of the distal Coronary Sinus (CS) bundles, the ridge and the saddle; 2) the standard PV isolation; 3) and finally ablation of the mitral line, the roof and of the cavo-tricuspid isthmus, main causes of recurrence in atrial flutter. Before ablation procedure patients will be randomized in 2 arms: Marshall Plan (treatment arm) or pulmonary vein isolation (control arm). Patients will be followed at 3, 6, 9 and 12 months in-office visits or hospitalization. Patients will have different tests: electrocardiogram (ECG), cardiac echography, stress test, 24hours Holter and transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
120
Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
Achievement of a wide disconnection of the right and left pulmonary veins.
Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
Bordeaux University Hospital
Pessac, France
Recurrence of AF or AT greater than 30 seconds with or without antiarrhythmic medications.
Recurrence rate (percentage) of AF or AT \> 30 seconds after the blanking period of 3-months post ablation, at 12 months with or without antiarrhythmic medications. Recurrences will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.
Time frame: 12 months
Recurrence of AF greater than 30 seconds
Recurrence rate (percentage) of AF greater than 30 seconds after the blanking period of 3-months post procedure at 12 months. It will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.
Time frame: 12 months
Recurrence of AF or AT greater than 30 seconds without antiarrhythmic medications
Recurrence rate (percentage) of AF or AT \> 30 seconds after the blanking period of 3-months post ablation, at 12 months without antiarrhythmic medications. Recurrences will be identified through transtelephonic ECG monitor with weekly transmitted ECG and at any time in case of symptoms.
Time frame: 12 months
Rate of patients under antiarrhythmic medications
Percentage of patients
Time frame: 12 months
Number of patients with repeat procedures
Number of patients
Time frame: 12 months
Rate of periprocedural complications
Percentage of transient ischemic attack or stroke, cardiac tamponade, atrio-oesophageal fistula, pericarditis, complications at access site (hematoma, arteriovenous fistula, pseudoaneurysm).
Time frame: 12 months
AF discontinuation rate during procedure
Percentage of AF discontinuation
Time frame: 12 months
Per-procedure AF / AT inducibility rate
Percentage of per-procedure AF / AT inducibility
Time frame: 12 months
Mitral line block rate
Percentage of mitral line block according to consensus block criteria
Time frame: 12 months
Radiofrequency duration necessary for pulmonary veins isolation
Duration measured in seconds
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.